市場調查報告書

全球置入式藥物輸送設備市場 - 各產品類型、技術、用途、地區 - 成長率,市場趨勢,市場預測(2018年∼2023年)

Implantable Drug Delivery Devices Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 707340
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
全球置入式藥物輸送設備市場 - 各產品類型、技術、用途、地區 - 成長率,市場趨勢,市場預測(2018年∼2023年) Implantable Drug Delivery Devices Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

全球置入式藥物輸送設備市場,預計從2018年到2023年,以7.8%的年複合成長率發展。由於基因學、蛋白質體學、生物科技領域的技術發展和新藥的登場,促進置入式藥物輸送設備市場成長。

本報告提供全球置入式藥物輸送設備市場調查,市場概要,各產品類型、技術、用途、地區的市場規模的變化與預測,市場趨勢,市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 置入式藥物輸送設備市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 成長要素
    • 微創手術的需求高漲
    • 新產品的登場
    • 慢性疾病的盛行率的上升
  • 阻礙因素
    • 設備的成本高
    • 嚴格的法規方案
  • 市場機會
  • 主要課題

第7章 置入式藥物輸送設備市場:各市場區隔

  • 各產品類型
    • 藥物輸液幫浦
    • 眼內藥物輸送設備
    • 避孕藥物輸送設備
    • 支架
  • 各技術
    • 生物分解性植入
    • 非生物分解性植入
  • 各用途
    • 腫瘤學
    • 心血管
    • 自體免疫疾病
    • 婦產科
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 企業簡介和競爭情形

  • Abbott
  • Allergan
  • Boston Scientific Corporation
  • Bausch and Lomb Inc.
  • Delpor Inc.
  • Medtronic
  • Novartis
  • pSivida Corp.
  • Teleflex Incorporated
  • 3M's Health Care

第9章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 62809

The implantable drug delivery devices market is expected to witness robust growth due to the recent developments taking place in genomics, proteomics and biotechnology that have led to emerging classes of novel pharmaceutical compounds across the globe that helps to accelerate the market. Furthermore, an increase in the burden of chronic diseases is affecting the large patient population which increases the number of surgeries and hence drives the implantable drug delivery devices market. According to the World Health Organization (WHO) 2017, chronic diseases are the major cause of disabilities worldwide. The estimated global burden by 2020 would be 60% and moreover, 73% of deaths in 2020 is expected due to chronic diseases. However, the high cost of devices and surgery costs, low rate of adoption are the few restraining factors of the growth of implantable drug delivery devices market.

Key Market Trends

Infusion pumps segment holds significant market share

Infusion pumps are devices that are used to deliver fluids into a patient's body, in a controlled manner. They are capable of supplying medications such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers. Infusion pumps play an important role in delivering accurate medications in chemotherapy, for diabetics, etc., for the corresponding diseases. The rising number of diabetes cases and increasing investments in diabetes care and management have helped in the adoption of insulin infusion pumps. Technological advancements, coupled with increasing R&D initiatives on gastrointestinal disorders, cancer, neurological problems, and AIDS, are providing lucrative opportunities for infusion pumps in the market. According to the FDA, in 2017, Baxter's Sigma Spectrum Infusion pump has been the number one infusion pump in drug library compliance. Sigma Spectrum has a user interface that provides top-quality patient safety margins and has the ability to integrate with leading electronic medical record systems.

North America Dominates the Implantable Drug Delivery Devices Market

In North America, the medical device industry is a highly regulated sector of the economy. There are several studies that suggest that the US manufacturers of implantable devices can maintain high prices, in part due to structural barriers such as costly regulatory approval processes and patent protections. Therefore, manufacturers face problems in launching new products in the United States. Hospitals are the primary purchasers of most high-cost implantable devices in the United States, but they have limited bargaining power to negotiate for lower prices. There are millions of Americans being implanted with implantable devices such as artificial hips or cardiac pacemakers, in their bodies. Experts have also estimated that 7.2 million Americans are living with joint implants. However, due to the aging population and the increasing prevalence of chronic conditions, the number of patients adopting implantable devices continues to grow exponentially. During the past year, in the United States, there have been many advancements in technology and medical innovation, which have expanded the types of implantable devices, to include artificial hearts and deep-brain stimulators to control epilepsy.

Competitive Landscape

Market players are focusing on new product launches, minimizing the price of the tests in order to gain maximum traction in the global market. Furthermore, market players are concentrating on various growth strategies such as collaborations, acquisitions, partnerships to enhance their market presence. For instance, Jan 2018: Medtronic Plc has received FDA approval of a new clinician programmer for use with the SynchroMed(TM) II Intrathecal Drug Delivery system, an implantable pump that provides targeted drug delivery for chronic pain and severe spasticity. Major market players are Boston Scientific Corporation, Bausch and Lomb Inc., Delpor Inc., Medtronic, pSivida Corp. and Teleflex Incorporated among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Minimally Invasive Procedures
    • 4.2.2 Emergence of Novel Products
    • 4.2.3 Increasing Prevalence of Chronic Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Devices
    • 4.3.2 Stringent Regulatory Requirements
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Drug Infusion Pumps
    • 5.1.2 Intraocular Drug Delivery Devices
    • 5.1.3 Contraceptive Drug Delivery Devices
    • 5.1.4 Stents
    • 5.1.5 Others
  • 5.2 By Technology
    • 5.2.1 Biodegradable Implants
    • 5.2.2 Non-biodegradable Implants
  • 5.3 By Application
    • 5.3.1 Oncology
    • 5.3.2 Cardiovascular
    • 5.3.3 Autoimmune Diseases
    • 5.3.4 Obstetrics and Gynecology
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Bausch and Lomb Inc.
    • 6.1.4 Delpor Inc.
    • 6.1.5 Medtronic
    • 6.1.6 Novartis (Alcon)
    • 6.1.7 pSivida Corp.
    • 6.1.8 Teleflex Incorporated
    • 6.1.9 DSM Biomedical
    • 6.1.10 TissueGen, Inc.
    • 6.1.11 3M

7 MARKET OPPORTUNITIES AND FUTURE TRENDS